Visionaries dare to make the world a better place
Cellgen Diagnostics is a privately held molecular diagnostics company that is developing a new class of diagnostics called PHARMACODYNAMICS (PD), which can be leveraged across multiple disease states throughout the continuum of patient healthcare. Pharmacodynamics differs from Pharmacogenomics (PG) in that pharmacogenomics measures how drugs will metabolize in the body. Cellgen’s pharmacodynamics platform, on the other hand, offers a dynamic measurement to predict the body’s response to a particular drug based on a genetic expression of a multi-parameter biomarker signature.
Current tissue-based molecular test methodologies limit personalized medicine to patients with actionable DNA mutations or aberrations, which only represents approximately 30% of the population. Blood-based diagnostics, on the other hand, are aggressively addressing the barriers of adoption and will help to revolutionize disease research, patient treatment, and survivor care. Cellgen’s therapeutic guidance platform will incorporate machine learning to deliver intelligent quantitative and actionable results to clinicians in 2 hours. Cellgen is poised to take advantage of the projected multibillion-dollar market growth in the field of personalized medicine by partnering with clinicians and payers to develop predictive tests that would enhance patient outcomes, avoid trial and error prescribing and reduce toxicity risk. Located in beautiful San Diego, CA, Cellgen licensed its original technology from the
Cellgen Diagnostics and Genomic Testing Cooperative Partner to Establish a New Standard in Co-Development of Companion Diagnostics for Cancer Therapies
Alliance will enable a faster and more rigorous approach to biomarker discovery and companion diagnostic co-development
University of California San Diego (UCSD) and began its operations in mid-2015. Additional engineering and clinical development transformed the academic technology into a scalable platform ideally suited for convenient point-of-care (PoC) utility.
Cellgen’s Platform Technology
In addition to the healthcare market, Cellgen will have the opportunity to expand the commercialization of its platform to four additional high value markets including life science research tools, agriculture and food pathogen testing, biological safety testing and veterinary and livestock testing. In addition, out-licensing deals to these markets will accelerate platform commercialization and reduce capital requirements and risk.
42 percent of all drugs in the pipeline have a companion diagnostic
Oncology leads the way with 73 percent of the pipeline represented by precision therapies
Biopharmaceutical companies nearly doubled their R&D investment in precision medicines over the past five years, and expect to increase their investment by an additional one-third in the next five years
Biopharmaceutical researchers forecast a 69 percent increase in the number of precision medicines in development over the next five years.